Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine,and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma
Yuankai Shi Ping Zhou Xiaohong Han Xiaohui He Shengyu Zhou Peng Liu Jianliang Yang
癌症(英文版)2015,Vol.34Issue(11):522-530,9.
癌症(英文版)2015,Vol.34Issue(11):522-530,9.DOI:10.1186/s40880-015-0045-3
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine,and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine,and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma
摘要
关键词
Stem cell transplantation/Mobilization/CHOP regimen/Rituximab/Non-Hodgkin's lymphomaKey words
Stem cell transplantation/Mobilization/CHOP regimen/Rituximab/Non-Hodgkin's lymphoma引用本文复制引用
Yuankai Shi,Ping Zhou,Xiaohong Han,Xiaohui He,Shengyu Zhou,Peng Liu,Jianliang Yang..Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine,and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma[J].癌症(英文版),2015,34(11):522-530,9.基金项目
This work was supported in part by Grants from National Science-Technology Support Plan Projects of China (2014BAI09B12),National Major Project for New Drug Innovation of China (2008ZX09312 and 2012ZX09303012),and the Ministry of Education Doctor Foundation of China (20010023018,20050023045,and 200800230019). (2014BAI09B12)